低用量ディゴキシンが心不全,エジェクション分数保存,心房動の患者における心機能を改善する - RATE- AFランダム化試験

Karina V Bunting^1,2, Asgher Champsi^1,3,4, Simrat K Gill^1,2

¹Institute of Cardiovascular Science, University of Birmingham, Birmingham, UK.

European journal of heart failure

|September 2, 2025

まとめ

低用量ディゴキシンは,永久的な心房細動と保存されたエジェクション分子を有意に改善した. ディゴキシンはまた症状と有害事象を軽減しました.

科学分野:

心臓病科
薬理学について
心不全研究

背景:

常発性心房細動 (AF) はしばしば心不全と共存する.
左心室 (LV) の機能は,心不全患者の管理において極めて重要です.
AFにおける心不全の最適な治療には,LV機能の影響を慎重に検討する必要があります.

研究の目的:

左心室機能に対するディゴキシンとベータブロッカーの効果を比較する.
永久性心房細動および心不全の症状を有する患者の静脈および静脈機能への影響を評価する.
心不全の症状と有害事象を含む臨床結果の評価.

主な方法:

RATE- AFランダム化試験では,低用量ディゴキシンとβ阻害剤を比較した.
ブラインドエコーカルディオグラムで,シストリック機能とダイアストリック機能の評価は,初期と12ヶ月間に行われました.
分析はベースライン左心室射出分数 (LVEF) によって分層化.

主要な成果:

保存されたLVEF (≥50%) の患者では,ディゴキシンはベータブロッカーと比較して,LVEF,s',および脳卒中量の有意な改善を示しました.
ディゴキシンは,N端のプロB型ナトリウレチンペプチドのレベルを低下させ,機能的および不律症の症状を改善した.
ディゴキシンはベータブロッカーよりもかなり少ない有害事象と関連していました.

結論:

低用量ディゴキシンは,永久性心筋梗塞と保存されたLVEFの患者の内静脈機能の改善をベータブロッカーと比較して提供します.
この特定の患者集団において,ディゴキシンが心不全のマーカーを軽減し,症状を改善し,有害事象を軽減する効果を示しています.

キーワード:

心房細動ベータブロッカーディゴキシンエコカルディオグラフィー発射分子が保存された心不全ランダム化制御試験

さらに関連する動画

12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

関連する概念動画

01:26

Heart Failure Drugs: Inotropic Agents

717

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

717

01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

01:22

Heart Failure Drugs: Diuretics

483

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

483

01:22

Heart Failure Drugs: β-Blockers

434

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

434

01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

505

関連する実験動画